U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H21F3N2O3S.ClH
Molecular Weight 438.892
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PNU-177864 HYDROCHLORIDE

SMILES

Cl.CCCNCCC1=CC=C(NS(=O)(=O)C2=CC=C(OC(F)(F)F)C=C2)C=C1

InChI

InChIKey=UOMDLHQTLPWCCE-UHFFFAOYSA-N
InChI=1S/C18H21F3N2O3S.ClH/c1-2-12-22-13-11-14-3-5-15(6-4-14)23-27(24,25)17-9-7-16(8-10-17)26-18(19,20)21;/h3-10,22-23H,2,11-13H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula C18H21F3N2O3S
Molecular Weight 402.431
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PNU-177864 is a selective antagonist of D3 receptor. Compound was considered as a drug candidate for the chronic treatment of schizophrenia, but severe myopathy was found in skeletal muscles of rats during the initial safety evaluation of PNU-177864. Myopathy was associated with phospholipidosis in numerous tissues.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35462
Gene ID: 1814.0
Gene Symbol: DRD3
Target Organism: Homo sapiens (Human)
38.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence.
2004 May-Jun
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
2017 Jan 18
Patents

Sample Use Guides

In preclinical toxicology studies phospholipidosis was observed when PNU-177864 was administered to rats orally at doses >= 80 mg/kg/day or to dogs at doses >= 32 mg/kg/day.
Route of Administration: Oral
Binding assay was performed using over-expressing human D3 CHO cell lines. [3H]-7-OH-DPAT (Kd for D3 1.4 nM) was used a radioligand. Membrane radioligand levels were determined by liquid scintillation counting. Non-specific binding was determined by radioligand binding in the presence of a saturating concentration of haloperidol. PNU-177864 binds to D3 receptors with Ki of 38.2 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:03:38 GMT 2023
Edited
by admin
on Sat Dec 16 19:03:38 GMT 2023
Record UNII
FH43729Z9T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PNU-177864 HYDROCHLORIDE
Common Name English
BENZENESULFONAMIDE, N-(4-(2-(PROPYLAMINO)ETHYL)PHENYL)-4-(TRIFLUOROMETHOXY)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
56972219
Created by admin on Sat Dec 16 19:03:38 GMT 2023 , Edited by admin on Sat Dec 16 19:03:38 GMT 2023
PRIMARY
CAS
1783978-03-9
Created by admin on Sat Dec 16 19:03:38 GMT 2023 , Edited by admin on Sat Dec 16 19:03:38 GMT 2023
PRIMARY
FDA UNII
FH43729Z9T
Created by admin on Sat Dec 16 19:03:38 GMT 2023 , Edited by admin on Sat Dec 16 19:03:38 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY